NZCR is led by the Research Physicians who established Christchurch Clinical Studies Trust (1999) and Auckland Clinical Studies (2006).
Home / Sponsors / Our Expertise
Our areas of expertise are:
Early in human Phase 1 – IV studies in healthy participants and patient populations.
This supports our research in the following key indications.
Dr Nick Cross
Dr Tim King
Dr Helen Evans (Paediatrics)
Dr Jeffrey Ngu
Dr Tony Rahman
Dr Jennifer McLaughlan
Dr Jane Kerr
Dr Ole Schmiedel
Dr Hilary Longhurst
Dr Patrick Gladding
Dr Gina O’Grady (Paediatrics)
Dr Mike Epton
Dr Oliver Comyn
Dr Hiliary Longhurst
NZCR is at the forefront of early phase clinical research. Our focus on quality and innovation has resulted in many exciting medical breakthroughs. This has included development of break-through therapies for many previously untreatable diseases, including hepatitis, cystic fibrosis, paroxysmal nocturnal haemoglobinuria, alpha-1-antitrypsin deficiency and neuromuscular diseases.
NZCR Research highlights
As ACS and CCST and with our partnering medical specialists, we are at the forefront of clinical research. Examples of our research highlights are as follows:
Lawitz C; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson RA; Maliakkal BJ; Gordon SC; Gane EJ. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open label study. Lancet Gastroenteraol Hepatol 2020: June 9; 1-9.
Kirschbrown WP, Wynne C, Kågedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg Amit. Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study. Journal of Clin Pharm. 2019 May: 59(5):702-716.
Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, Leiter LA, Kastelein JJP, Ray KK, Kallend D. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2020 Jan;95(1):77-89.
Wynne C, Schwabe C, Vincent E, Schueler A, Ryding J, Ullmann M, Ghori V,Kanceva R, Stahl M. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double-blind trial.Pharmacol Res Perspect. 2020 Apr;8(2):e00578.
Wynne C, Schwabe C, Sachdeva Batra S, Lopez-Lazaro L, Kankanwadi S. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects. British Journal of Clinical Pharmacology. 2018 Oct:84(10):2352-2364.
New Zealand Clinical Research (NZCR) provides state of the art research facilities and the expertise to conduct complex early phase clinical research in healthy participant and patient populations.